CPT1A and ovarian carcinoma: Mechanistic studies emphasized that miR-33b directly targets TAK1, which leads to downregulation of FASN and CPT1A, explaining the inhibitory effects of miR-33b on the lipid metabolic activities of ovarian cancer cells.